Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

Link Type

Funded-research

Media Type

Article

Publish or Event Date

Tue, 09/27/2022 - 12:00pm

Link URL

https://moleculin.com/moleculin-biotech-wp1122-portfolio-compound-wp1096-selected-for-niaid-funded-animal-studies-as-novel-potential-antiviral/

Research Institution

Moleculin Biotech

Short Title

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

Content Coordinator

Content Manager

For Researchers